Will Equillium’s Itolizumab emerge the winner in the COVID-19 sweepstakes?
Equillium Bio (NASDAQ: EQ), a clinical–stage biopharmaceutical Company focused on bringing innovation in form of immune-modifying therapies to treat immuno-inflammatory diseases, announced the receipt of a Study May Proceed letter from the U.S Food and Drug Administration (FDA), to evaluate the company’s lead asset itolizumab,...
